Publications by authors named "Ellen Apperloo"
Objective: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes and high cardiovascular risk in the SURPASS-4 trial. To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials.
Research Design And Methods: This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Article Synopsis
- Semaglutide, a drug for type 2 diabetes, shows promise in reducing albuminuria and slowing kidney disease progression in patients with chronic kidney disease (CKD) in a double-blind clinical trial.
- The study involved 101 participants, comparing those receiving 2.4 mg of semaglutide weekly to a placebo, with a focus on changes in urine albumin-to-creatinine ratio after 24 weeks.
- Results indicated a significant 52.1% reduction in albuminuria for the semaglutide group, although gastrointestinal side effects were more common compared to the placebo group.
Article Synopsis
- SGLT2 inhibitors and GLP-1 receptor agonists both have positive effects on cardiovascular and kidney health in patients with type 2 diabetes, leading to a study comparing their benefits when used together or separately.
- A meta-analysis from various trials showed that SGLT2 inhibitors effectively reduced risks of major cardiovascular events and kidney disease progression for patients whether or not they were taking GLP-1 receptor agonists.
- The consistency of these benefits across different outcomes indicates that SGLT2 inhibitors can be beneficial for all diabetic patients, regardless of GLP-1 receptor agonist usage.
Background And Hypothesis: This post-hoc analysis explored the semaglutide effects on eGFR slope by baseline glycemic control, blood pressure (BP), body mass index (BMI), and albuminuria status in people with type 2 diabetes and high cardiovascular risk.
Methods: Pooled SUSTAIN 6 and PIONEER 6 data were analyzed for change in estimated glomerular filtration (eGFR) slope by baseline HbA1c (<8%/≥8%; <64 mmol/mol/≥64 mmol/mol), systolic BP (<140/90 mmHg/≥140/90 mmHg), and BMI (<30 kg/m2/≥30 kg/m2). SUSTAIN 6 data were analyzed by baseline urinary albumin: creatinine ratio (UACR; <30/30 - 300/>300 mg/g).
Aim: To evaluate the albuminuria-lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria.
Methods: Participants with type 2 diabetes, an estimated glomerular filtration rate (eGFR) of more than 30 ml/min/1.73m and an urinary albumin: creatinine ratio (UACR) of more than 3.
Objective: These post hoc analyses of the Semaglutide Treatment Effect in People with obesity (STEP) 1-3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the effects of semaglutide (up to 2.4 mg) on kidney function.
Research Design And Methods: STEP 1-3 included adults with overweight/obesity; STEP 2 patients also had type 2 diabetes.
Aims: To assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating renin angiotensin aldosterone system (RAAS) inhibition, and to assess the association of response variability with cardiovascular outcomes.
Material And Methods: We performed an observational cohort study in patients with type 2 diabetes who started RAAS inhibition between 2007 and 2013 (n = 1600). Patients were identified from general practices in the Netherlands.